Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCash from Financing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Fennec Pharmaceuticals (FENC) Free Cash Flow (2016 - 2025)

Fennec Pharmaceuticals' Free Cash Flow history spans 15 years, with the latest figure at -$6.0 million for Q4 2025.

  • For the quarter ending Q4 2025, Free Cash Flow fell 304.48% year-over-year to -$6.0 million, compared with a TTM value of -$12.5 million through Dec 2025, down 149.42%, and an annual FY2025 reading of -$12.5 million, down 146.23% over the prior year.
  • Free Cash Flow for Q4 2025 was -$6.0 million at Fennec Pharmaceuticals, down from $1.5 million in the prior quarter.
  • The five-year high for Free Cash Flow was $37.3 million in Q1 2024, with the low at -$8.4 million in Q2 2024.
  • Average Free Cash Flow over 5 years is -$1.6 million, with a median of -$3.6 million recorded in 2021.
  • Year-over-year, Free Cash Flow skyrocketed 768.94% in 2024 and then tumbled 304.48% in 2025.
  • Tracing FENC's Free Cash Flow over 5 years: stood at -$3.0 million in 2021, then tumbled by 129.95% to -$6.8 million in 2022, then increased by 28.55% to -$4.9 million in 2023, then skyrocketed by 69.67% to -$1.5 million in 2024, then tumbled by 304.48% to -$6.0 million in 2025.
  • Per Business Quant, the three most recent readings for FENC's Free Cash Flow are -$6.0 million (Q4 2025), $1.5 million (Q3 2025), and -$3.7 million (Q2 2025).